The TreatmentTrends: Rheumatoid Arthritis 2014 (EU) report explores the treatment dynamics among more than 200 French, German, Italian, Spanish, and UK rheumatologists through comprehensive primary research methods and how these have evolved in recent years. The use of biologic products prescribed for rheumatoid arthritis is covered in particular detail. The report explores rheumatologists’ awareness, trial, and usage of currently available brands, as well as familiarity with and interest in key emerging therapies.
Questions Answered in This Report:
- The use of biologic agents to treat rheumatoid arthritis has remained relatively constant since 2012. Is there remaining opportunity for novel biologic agents in the crowded rheumatoid arthritis landscape?
- Brand share has shifted away from the established tumor necrosis factor-alpha (TNF-α) inhibitors toward the more recently launched products. How do European rheumatologists anticipate market shares will evolve in the future?
- The first biosimilar agent for use in immunological indications including rheumatoid arthritis is expected to launch in European markets in the near future. How will the availability of biosimilar agents affect rheumatologists’ prescribing habits?
Markets covered: France, Germany, Italy, Spain, United Kingdom.
Sample frame: 244 European rheumatologists currently in clinical practice, treating a minimum of 5 rheumatoid arthritis patients with a biologic agent.
Methodology: 45-minute, online survey with several open-ended questions for qualitative feedback.